ORTX — Orchard Therapeutics Share Price
0.000.00%
Last trade - 00:00- $378.06m
- $278.24m
- $22.66m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.71 | ||
| Price to Tang. Book | 4.91 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 17.31 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -66.73% | ||
| Return on Equity | -71.5% | ||
| Operating Margin | -467.13% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.08 | 2.51 | 2.6 | 1.68 | 22.66 | 27.9 | 53.49 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Orchard Therapeutics plc is a gene therapy company. The Company is engaged in transforming the lives of people affected by rare diseases through the development of curative gene therapies. Its ex vivo autologous hematopoietic stem cell (HSC), gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. Its ex vivo autologous HSC gene therapy approach seeks to transform a patient’s autologous HSCs into a gene-modified cellular drug product to treat the patient’s disease. Its lead program is OTL-200 operates under the brand name Libmeldy for eligible patients with early-onset metachromatic leukodystrophy (MLD). Its programs in immunological disorders consist of two pre-clinical programs, OTL-104 for Crohn’s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD), and OTL-105 for hereditary angioedema (HAE).
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- August 1st, 2018
- Public Since
- October 31st, 2018
- No. of Shareholders
- 56
- No. of Employees
- 166
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 227,610,439
- Address
- 245 Hammersmith Road, 3Rd Floor, London, W6 8PW
- Web
- https://www.orchard-tx.com/
- Phone
- +44 2038088286
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for ORTX
Q1 2024 Orchard Therapeutics PLC Earnings Release
Orchard Therapeutics PLC Annual Shareholders Meeting
Similar to ORTX
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Affinia Therapeutics
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
FAQ
What is the Orchard Therapeutics share price?
As of Today at 18:16 UTC, shares in Orchard Therapeutics are trading at $16.61. This share price information is delayed by 15 minutes.
How has the Orchard Therapeutics share price performed this year?
Shares in Orchard Therapeutics last closed at $16.61 and the price had moved by +160.34% over the past 365 days. In terms of relative price strength the Orchard Therapeutics share price has outperformed the S&P500 Index by +113.7% over the past year.
What are the analyst and broker recommendations for Orchard Therapeutics?
The overall consensus recommendation for Orchard Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Orchard Therapeutics dividend yield?
Orchard Therapeutics does not currently pay a dividend.
Does Orchard Therapeutics pay a dividend?
Orchard Therapeutics does not currently pay a dividend.
When does Orchard Therapeutics next pay dividends?
Orchard Therapeutics does not currently pay a dividend.
How do I buy Orchard Therapeutics shares?
To buy shares in Orchard Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Orchard Therapeutics?
As of the previous close price of $16.61, shares in Orchard Therapeutics had a market capitalisation of $378.06m.
Where are Orchard Therapeutics shares listed?
Here are the trading details for Orchard Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ORTX
What kind of share is Orchard Therapeutics?
Based on an overall assessment of its quality, value and momentum Orchard Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Orchard Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Orchard Therapeutics is $16.00. That is 3.67% below the last closing price of $16.61.
Analysts covering Orchard Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.89 for the next financial year.
Find out moreWhat is the trend in the Orchard Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Orchard Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +195.49%.
As of the last closing price of $16.61, shares in Orchard Therapeutics were trading +78.82% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Orchard Therapeutics PE Ratio?
The Orchard Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $16.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Orchard Therapeutics?
We do not have data on Orchard Therapeutics' directors